{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:49:47Z","timestamp":1790700587593,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007210","name":"Varian Medical Systems","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100007210","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ygyno.2021.03.017","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T01:00:31Z","timestamp":1617066031000},"page":"645-652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma"],"prefix":"10.1016","volume":"161","author":[{"given":"Duygu","family":"Sezen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshal R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Onstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyadharsini","family":"Nagarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapna P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilie L.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2021.03.017_bb0005","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijrobp.2005.06.030","article-title":"Combined-modality therapy for patients with regional nodal metastases from melanoma","volume":"64","author":"Ballo","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"11","key":"10.1016\/j.ygyno.2021.03.017_bb0010","first-page":"e23","article-title":"Mucosal melanoma: new insights and therapeutic options for a unique and aggressive disease","volume":"31","author":"Lerner","year":"2017","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.ygyno.2021.03.017_bb0015","series-title":"Cancer Staging Manual","author":"AJCC","year":"2017"},{"issue":"6","key":"10.1016\/j.ygyno.2021.03.017_bb0020","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J. Clin."},{"issue":"36","key":"10.1016\/j.ygyno.2021.03.017_bb0025","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2021.03.017_bb0030","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40257-019-00487-x","article-title":"Malignant melanoma of the vulva and vagina: a US population-based study of 1863 patients","volume":"21","author":"Wohlmuth","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"issue":"6","key":"10.1016\/j.ygyno.2021.03.017_bb0035","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1245\/s10434-014-4215-3","article-title":"Melanoma of the vulva and vagina: principles of staging and their relevance to management based on a clinicopathologic analysis of 85 cases","volume":"22","author":"Seifried","year":"2015","journal-title":"Ann. Surg. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2021.03.017_bb0040","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1470-2045(08)70254-7","article-title":"Management of primary melanoma of the female urogenital tract","volume":"9","author":"Piura","year":"2008","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2021.03.017_bb0045","doi-asserted-by":"crossref","first-page":"815","DOI":"10.5858\/arpa.2017-0435-RA","article-title":"Immunohistochemical expression of p16 in melanocytic lesions: an updated review and meta-analysis","volume":"142","author":"Koh","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.ygyno.2021.03.017_bb0050","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ajo.2020.09.033","article-title":"Immunohistochemical profiling of conjunctival melanocytic intraepithelial lesions, including Sox10, Hmb45, Ki67, and P16","volume":"222","author":"Milman","year":"2021","journal-title":"Am J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.03.017_bb0055","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11912-018-0675-0","article-title":"Mucosal melanoma: a literature review","volume":"20","author":"Yde","year":"2018","journal-title":"Curr. Oncol. Rep."},{"issue":"2","key":"10.1016\/j.ygyno.2021.03.017_bb0060","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and safety of nivolumab alone or in combination with Ipilimumab in patients with mucosal melanoma: a pooled analysis","volume":"35","author":"D\u2019Angelo","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.03.017_bb0065","author":"National Cancer Institute"},{"issue":"8","key":"10.1016\/j.ygyno.2021.03.017_bb0070","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G","article-title":"The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society","volume":"83","author":"Chang","year":"1998","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2021.03.017_bb0075","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/cncr.20866","article-title":"Incidence of noncutaneous melanomas in the U.S","volume":"103","author":"McLaughlin","year":"2005","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2021.03.017_bb0080","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejogrb.2004.11.048","article-title":"Primary malignant melanoma of the vagina: a case report and review of the current treatment options","volume":"121","author":"Gokaslan","year":"2005","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.03.017_bb0085","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ygyno.2018.04.562","article-title":"Melanoma of the lower genital tract: prognostic factors and treatment modalities","volume":"150","author":"Gadducci","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2021.03.017_bb0090","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jaad.2006.06.017","article-title":"Primary mucosal melanoma","volume":"56","author":"Patrick","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"issue":"8","key":"10.1016\/j.ygyno.2021.03.017_bb0095","first-page":"739","article-title":"Primary mucosal melanomas: a comprehensive review","volume":"5","author":"Mihajlovic","year":"2012","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.03.017_bb0100","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/bjd.12421","article-title":"Genital and anorectal mucosal melanoma is associated with cutaneous melanoma in patients and in families","volume":"169","author":"Cazenave","year":"2013","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.ygyno.2021.03.017_bb0105","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1102\/1470-7330.2013.0055","article-title":"Metastatic mucosal melanoma: imaging patterns of metastasis and recurrence","volume":"13","author":"O\u2019Regan","year":"2013","journal-title":"Cancer Imaging"},{"issue":"15","key":"10.1016\/j.ygyno.2021.03.017_bb0110","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.ejca.2012.06.013","article-title":"Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012","volume":"48","author":"Garbe","year":"2012","journal-title":"Eur. J. Cancer"},{"issue":"9 Suppl 3","key":"10.1016\/j.ygyno.2021.03.017_bb0115","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1097\/IGC.0000000000000198","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus review for vulvovaginal melanomas","volume":"24","author":"Leitao","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"16","key":"10.1016\/j.ygyno.2021.03.017_bb0120","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.1158\/1078-0432.CCR-13-0739","article-title":"Phase II randomized trial comparing high-dose IFN-alpha2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma","volume":"19","author":"Lian","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.ygyno.2021.03.017_bb0125","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ygyno.2013.02.028","article-title":"Vulvar and vaginal melanoma: case series and review of current management options including neoadjuvant chemotherapy","volume":"129","author":"Janco","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2021.03.017_bb0130","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/00008390-200412000-00012","article-title":"Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma","volume":"14","author":"Harting","year":"2004","journal-title":"Melanoma Res."},{"issue":"2","key":"10.1016\/j.ygyno.2021.03.017_bb0135","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.critrevonc.2011.03.008","article-title":"A literature overview of primary cervical malignant melanoma: an exceedingly rare cancer","volume":"81","author":"Pusceddu","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"5","key":"10.1016\/j.ygyno.2021.03.017_bb0140","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/CCO.0b013e32830b0dda","article-title":"Management of melanomas of the female genital tract","volume":"20","author":"Sugiyama","year":"2008","journal-title":"Curr. Opin. Oncol."},{"issue":"26","key":"10.1016\/j.ygyno.2021.03.017_bb0145","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.ygyno.2021.03.017_bb0150","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","article-title":"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin","volume":"31","author":"Hodi","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.ygyno.2021.03.017_bb0155","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1002\/cncr.30663","article-title":"A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: a trial of the ECOG-ACRIN Cancer Research Group (E2607)","volume":"123","author":"Kalinsky","year":"2017","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ygyno.2021.03.017_bb0160","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1080\/14740338.2017.1382472","article-title":"High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions","volume":"16","author":"Marabondo","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"issue":"8","key":"10.1016\/j.ygyno.2021.03.017_bb0165","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.ygyno.2021.03.017_bb0170","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of Ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.03.017_bb0175","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2013.09.007","article-title":"Efficacy and safety of ipilimumab 3mg\/kg in patients with pretreated, metastatic, mucosal melanoma","volume":"50","author":"Del Vecchio","year":"2014","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2021.03.017_bb0180","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1634\/theoncologist.2012-0464","article-title":"Ipilimumab for patients with advanced mucosal melanoma","volume":"18","author":"Postow","year":"2013","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.ygyno.2021.03.017_bb0185","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00262-019-02351-7","article-title":"Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma","volume":"68","author":"Moya-Plana","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"issue":"21","key":"10.1016\/j.ygyno.2021.03.017_bb0190","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1002\/cncr.30259","article-title":"The efficacy of anti-PD-1 agents in acral and mucosal melanoma","volume":"122","author":"Shoushtari","year":"2016","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ygyno.2021.03.017_bb0195","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"9948","key":"10.1016\/j.ygyno.2021.03.017_bb0200","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2021.03.017_bb0205","first-page":"137908","article-title":"Vaginal primary malignant melanoma: a rare and aggressive tumor","volume":"2013","author":"Androutsopoulos","year":"2013","journal-title":"Case Rep. Obstet. Gynecol."},{"issue":"6","key":"10.1016\/j.ygyno.2021.03.017_bb0210","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1097\/AOG.0b013e3181fb8045","article-title":"Primary malignant melanoma of the vagina","volume":"116","author":"Frumovitz","year":"2010","journal-title":"Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.ygyno.2021.03.017_bb0215","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/jrr\/rrt120","article-title":"Clinical trial of carbon ion radiotherapy for gynecological melanoma","volume":"55","author":"Karasawa","year":"2014","journal-title":"J. Radiat. Res."},{"issue":"3","key":"10.1016\/j.ygyno.2021.03.017_bb0220","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1006\/gyno.1998.5188","article-title":"Malignant melanoma of the vagina and locoregional control: radical surgery revisited","volume":"71","author":"Irvin","year":"1998","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2021.03.017_bb0225","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1097\/IGC.0b013e3182a1ced8","article-title":"Treatment approach and outcomes of vaginal melanoma","volume":"23","author":"Kirschner","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"305","key":"10.1016\/j.ygyno.2021.03.017_bb0230","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1259\/0007-1285-26-305-234","article-title":"Whole body irradiation; radiobiology or medicine?","volume":"26","author":"Mole","year":"1953","journal-title":"Br. J. Radiol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.03.017_bb0235","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13073-019-0653-7","article-title":"Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system","volume":"11","author":"Lhuillier","year":"2019","journal-title":"Genome Med."},{"issue":"2","key":"10.1016\/j.ygyno.2021.03.017_bb0240","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijrobp.2020.08.025","article-title":"Use of multi-site radiation therapy for systemic disease control","volume":"109","author":"Patel","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ygyno.2021.03.017_bb0245","first-page":"8(2)","article-title":"Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma","author":"Barsoumian","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2021.03.017_bb0250","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0039-6109(02)00096-8","article-title":"Radiation therapy for malignant melanoma","volume":"83","author":"Ballo","year":"2003","journal-title":"Surg. Clin. North Am."},{"issue":"6","key":"10.1016\/j.ygyno.2021.03.017_bb0255","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/0360-3016(86)90378-0","article-title":"The role of radiotherapy in recurrent and metastatic malignant melanoma: a clinical radiobiological study","volume":"12","author":"Overgaard","year":"1986","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.ygyno.2021.03.017_bb0260","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0167-8140(89)90017-0","article-title":"Clinical radiobiology of malignant melanoma","volume":"16","author":"Bentzen","year":"1989","journal-title":"Radiother. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2021.03.017_bb0265","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1158\/0008-5472.CAN-15-3142","article-title":"Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy","volume":"77","author":"Wang","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2021.03.017_bb0270","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12967-014-0262-6","article-title":"Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response","volume":"12","author":"Ridolfi","year":"2014","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.ygyno.2021.03.017_bb0275","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000505487","article-title":"Systemic antitumor effects and abscopal responses in melanoma patients receiving radiation therapy","volume":"98","author":"D\u2019Andrea","year":"2020","journal-title":"Oncology"},{"key":"10.1016\/j.ygyno.2021.03.017_bb0280","article-title":"Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials","author":"Theelen","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"5","key":"10.1016\/j.ygyno.2021.03.017_bb0285","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2021.03.017_bb0290","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1634\/theoncologist.2019-IO-S1-s04","article-title":"The role of radiation oncology in immuno-oncology","volume":"24","author":"Meng","year":"2019","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.ygyno.2021.03.017_bb0295","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s40425-019-0718-6","article-title":"Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy","volume":"7","author":"Menon","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.ygyno.2021.03.017_bb0300","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1158\/2326-6066.CIR-18-0793","article-title":"Phase II trial of Ipilimumab with stereotactic radiation therapy for metastatic disease: outcomes, toxicities, and low-dose radiation-related abscopal responses","volume":"7","author":"Welsh","year":"2019","journal-title":"Cancer Immunol Res"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821002535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821002535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:48:39Z","timestamp":1715820519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821002535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0090825821002535"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.03.017","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}